Snoring, Sleep Apnea Linked to Dementia, but CPAP Helps

This article originally appeared here.
Share this content:
Snoring, Sleep Apnea Linked to Dementia, but CPAP Helps
Snoring, Sleep Apnea Linked to Dementia, but CPAP Helps

THURSDAY, April 16, 2015 (HealthDay News) -- People with sleep-disordered breathing (SDB) may be more likely to develop mild cognitive impairment (MCI) at younger ages than those without SDB, a new study suggests. The report was published online April 15 in Neurology.

Ricardo Osorio, M.D., a research assistant professor of psychiatry at New York University's Center for Cognitive Neurology in New York City, and colleagues reviewed the medical records of 2,470 people. Patients were between 55 and 90 years old and were classified one of three ways: free of cognitive impairment, in the early stages of MCI, or with Alzheimer's disease. The researchers compared people with untreated SDB to those without SDB. The authors also compared people who had untreated SDB to those who received treatment with continuous positive airway pressure (CPAP).

Osorio and his colleagues found that people with SDB were diagnosed with MCI about 10 years or more sooner than those who didn't have SDB. For example, heavy snorers and those with sleep apnea who developed MCI developed it when they were around 77, while those without SDB didn't develop MCI until they were around 90, Osorio told HealthDay. Among people who developed Alzheimer's disease, those with SDB developed it when they were about 83, compared with age 88 for those without SDB, he said.

However, people with sleep apnea treated with CPAP who developed MCI developed it about 10 years later than those whose SDB wasn't treated -- 82 versus 72 years.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths